Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8NI32
UPID:
LPD6B_HUMAN
Alternative names:
-
Alternative UPACC:
Q8NI32; D3DP90; Q53TK0; Q7Z747; Q8IXK7
Background:
Ly6/PLAUR domain-containing protein 6B plays a pivotal role in modulating nicotinic acetylcholine receptors (nAChRs), crucial for neurotransmission. It acts in a subtype- and stoichiometry-dependent manner, particularly influencing alpha-3(3):beta-4(2) nAChRs by enhancing sensitivity to acetylcholine, modulating maximal current response, and altering desensitization rates. Notably, it exhibits a distinct interaction with alpha-7 homomeric nAChRs and alpha-3(2):alpha-5:beta-4(2) nAChRs based on the CHRNA5/alpha-5 variant.
Therapeutic significance:
Understanding the role of Ly6/PLAUR domain-containing protein 6B could open doors to potential therapeutic strategies, especially in disorders related to neurotransmission dysregulation.